Skip to main content
. 2020 May 4;35(11):1893–1901. doi: 10.1111/jgh.15063

Figure 2.

Figure 2

Association between fecal calprotectin (μg/g) and endoscopic response to vedolizumab at weeks 16 and 52. Receiver operating characteristic curves for the optimal fecal calprotectin cut‐off value to predict endoscopic response after vedolizumab induction at week 16 and week 52. The area under the curve for endoscopic response at week 16 = 0.860, for endoscopic remission at week 16 = 0828, and for sustained endoscopic response at week 52 = 0.942. Upper panel: Inline graphic, endoscopic response;Inline graphic, endoscopic remission. Lower panel: Inline graphic, sustained endoscopic response. [Color figure can be viewed at wileyonlinelibrary.com]